top of page

Why invest in Medical Cannabis for veterinary use?

The advancement of cannabinoid-based medicine is one of the most transformative movements in contemporary pharmacology. The first cannabis-based medication — Sativex — was approved by the EMA (European Medicines Agency) in 2018, followed by Epidiolex, approved by the FDA (United States) in 2019 for the treatment of refractory epilepsies. Since then, dozens of clinical trials involving cannabidiol (CBD)-based drugs have been conducted globally, particularly in the United States and Europe, focusing on neurological, inflammatory, and autoimmune diseases.

While the medical use of cannabis continues to advance based on robust evidence in human health, veterinary medicine still lacks regulated and scientifically validated solutions. Despite the absence of FDA-approved veterinary medications, the market already offers numerous CBD-based supplements—many without proven efficacy or quality control.

The therapeutic use of cannabidiol in animal health, however, is increasingly supported by scientific literature, with hundreds of studies published in peer-reviewed journals. Evidence shows promising benefits for conditions such as epilepsy, chronic pain, osteoarticular disorders, dermatitis, and anxiety in dogs and cats.

In this context, investing in medical cannabis for veterinary use represents a strategic opportunity in a market with high demand, limited availability of reliable pharmaceutical solutions, and growing acceptance among pet owners and animal health professionals. Vettiva is positioned at the forefront of this movement, with a focus on safety, clinical evidence, and regulatory rigor—from development to distribution.

gato e cachorro filhotes olhando para a câmera
31975-site-vettiva-imagem1.jpg

Medical  Cannabis for veterinary treatment in Brazil

In Brazil, there are currently around 45 Cannabis-based products approved by ANVISA, including isolated cannabidiol pharmaceuticals and full-spectrum plant extracts. In the veterinary field, despite promising evidence — from pain relief and seizure control to potential applications in distemper and cancer — there are still no formally registered medications for animal use. Nevertheless, pet owners across the country have obtained exceptional authorizations, recognizing that cannabidiol often offers greater efficacy and fewer side effects compared to conventional treatments.

31975-site-vettiva-imagem3.png

Advances for Pet Health and the Brazilian Economy

Vettiva's research advances are at the forefront of supporting innovation and the development of products and therapies for the treatment of thousands of animals in Brazil. Brazil is the country with the second largest population of domestic animals in the world, and the pet segment is driving the main growth in the national market (CAGR 7.1%, 2017-2024*), with a large market for innovative products.

 

We intend to be a national reference and distribute our medicines to several countries.

bottom of page